Bispecific antibodies in development for the treatment of multiple myeloma
| Name | Target antigen | Company | Trial ID |
| AMG-420 | BCMA | Amgen | NCT02514239 |
| AMG-701 | BCMA | Amgen | NCT03287908 |
| CC-93269 | BCMA | Celgene | NCT03486067 |
| PF-06863135 | BCMA | Pfizer | NCT03269136 |
| REGN-5458 | BCMA | Regeneron | NCT03761108 |
| TNB-383B | BCMA | Teneobio | NCT03933735 |
| JNJ-64007957 | BCMA | Johnson & Johnson/Genmab | NCT03145181 |
| JNJ-64007564 | GPRC5d | Johnson & Johnson/Genmab | NCT03399799 |
| GBR-1342 | CD38 | Glenmark | NCT03309111 |
| AMG-424 | CD38 | Amgen | NCT03445663 |
| BFCR4350A | FCRH5 | Genetech | NCT03275103 |